Active Biotech

Active Biotech (STO:ACTI) - Recruitment Still Ongoing For Second, Pivotal Phase III Study, Bravo - Jerusalem, Israel and Lund, Sweden, November 18, 2008 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completion of patient enrollment for the Phase III clinical trial, Allegro, in relapsing-remitting multiple sclerosis (RRMS). The pivotal Allegro study is designed to evaluate the efficacy, safety and tolerability of the oral investigational compound, laquinimod, versus placebo in the treatment of RRMS.

Active Biotech (STO:ACTI) - Laquinimod -- positive data presented from extension study

Active Biotech (STO:ACTI) Lund, Sweden, November 6, 2008 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at the New York Palace Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

Active Biotech (STO:ACTI) Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.

Active Biotech (STO:ACTI) Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.

Active Biotech (STO:ACTI) Lund, Sweden, October 17, 2008 - Active Biotech AB's (NASDAQ OMX Nordic: ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) today announce information regarding the candidate drug RhuDex® for the treatment of rheumatoid arthritis.

Active Biotech (STO:ACTI) - New Crossover Data Presented at the World Congress on Treatment and Research in Multiple Sclerosis Shows Significant Reduction of Gadolinium-Enhancing Lesions -

Active Biotech (STO:ACTI) Lund, Sweden, 17 September 2008 - Active Biotech (OMX Nordic: ACTI) is scheduled to present at the UBS Global Life Sciences Conference on Tuesday, September 23 at the Grand Hyatt Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided.

Active Biotech (ACTI.ST) * Laquinimod - enrolment for the Allegro and Bravo Phase III studies proceeding * ANYARA - Phase III study proceeding - Promising median survival from Phase I study * TASQ - Phase II studies for treatment of prostate cancer in progress * 57-57 - Phase Ib study against SLE successfully concluded * RhuDex® - Phase IIa study against RA presented positive findings * Tomas Leanderson new CEO from September 1 * Net sales SEK 5.8 M (5.8) * Operating result SEK -104.7 M (-108.5) * Result after tax SEK -99.3 M (-112.1) * Result per share for the period amounted to SEK -2.07 (-2.46)

Active Biotech (ACTI.ST) Sven Andréasson has notified the Board of his wish to resign from the position as President & CEO of Active Biotech AB.